Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy ImmuCell Corporation stock | $8.9101

Learn how to easily invest in ImmuCell Corporation stock.

ImmuCell Corporation is a biotechnology business based in the US. ImmuCell Corporation shares (ICCC) are listed on the NASDAQ and all prices are listed in US Dollars. ImmuCell Corporation employs 61 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in ImmuCell Corporation

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ICCC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

ImmuCell Corporation stock price (NASDAQ: ICCC)

Use our graph to track the performance of ICCC stocks over time.

ImmuCell Corporation shares at a glance

Information last updated 2021-10-17.
Latest market close$8.91
52-week range$5.21 - $12.09
50-day moving average $9.32
200-day moving average $9.58
Wall St. target price$14.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.06

Buy ImmuCell Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy ImmuCell Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ImmuCell Corporation price performance over time

Historical closes compared with the close of $8.9101 from 2021-10-22

1 week (2021-10-15) -3.99%
1 month (2021-09-24) -8.05%
3 months (2021-07-23) -12.99%
6 months (2021-04-23) -16.34%
1 year (2020-10-23) 56.32%
2 years (2019-10-23) 68.12%
3 years (2018-10-23) 5.57%
5 years (2016-10-21) 48.50%

Is ImmuCell Corporation under- or over-valued?

Valuing ImmuCell Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ImmuCell Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

ImmuCell Corporation's EBITDA

ImmuCell Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.4 million.

The EBITDA is a measure of a ImmuCell Corporation's overall financial performance and is widely used to measure a its profitability.

ImmuCell Corporation financials

Revenue TTM $16.1 million
Gross profit TTM $6.9 million
Return on assets TTM -1.55%
Return on equity TTM -1.43%
Profit margin -2.7%
Book value $4.17
Market capitalisation $71.8 million

TTM: trailing 12 months

Shorting ImmuCell Corporation shares

There are currently 10,422 ImmuCell Corporation shares held short by investors – that's known as ImmuCell Corporation's "short interest". This figure is 3.1% down from 10,760 last month.

There are a few different ways that this level of interest in shorting ImmuCell Corporation shares can be evaluated.

ImmuCell Corporation's "short interest ratio" (SIR)

ImmuCell Corporation's "short interest ratio" (SIR) is the quantity of ImmuCell Corporation shares currently shorted divided by the average quantity of ImmuCell Corporation shares traded daily (recently around 9223.0088495575). ImmuCell Corporation's SIR currently stands at 1.13. In other words for every 100,000 ImmuCell Corporation shares traded daily on the market, roughly 1130 shares are currently held short.

However ImmuCell Corporation's short interest can also be evaluated against the total number of ImmuCell Corporation shares, or, against the total number of tradable ImmuCell Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ImmuCell Corporation's short interest could be expressed as 0% of the outstanding shares (for every 100,000 ImmuCell Corporation shares in existence, roughly 0 shares are currently held short) or 0.0019% of the tradable shares (for every 100,000 tradable ImmuCell Corporation shares, roughly 2 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ImmuCell Corporation.

Find out more about how you can short ImmuCell Corporation stock.

ImmuCell Corporation share dividends

We're not expecting ImmuCell Corporation to pay a dividend over the next 12 months.

Have ImmuCell Corporation's shares ever split?

ImmuCell Corporation's shares were split on a 1:100 basis on 24 July 1990. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ImmuCell Corporation shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for ImmuCell Corporation shares which in turn could have impacted ImmuCell Corporation's share price.

ImmuCell Corporation share price volatility

Over the last 12 months, ImmuCell Corporation's shares have ranged in value from as little as $5.21 up to $12.09. A popular way to gauge a stock's volatility is its "beta".

ICCC.US volatility(beta: 0.87)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ImmuCell Corporation's is 0.8709. This would suggest that ImmuCell Corporation's shares are less volatile than average (for this exchange).

ImmuCell Corporation overview

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Frequently asked questions

What percentage of ImmuCell Corporation is owned by insiders or institutions?
Currently 28.456% of ImmuCell Corporation shares are held by insiders and 10.349% by institutions.
How many people work for ImmuCell Corporation?
Latest data suggests 61 work at ImmuCell Corporation.
When does the fiscal year end for ImmuCell Corporation?
ImmuCell Corporation's fiscal year ends in December.
Where is ImmuCell Corporation based?
ImmuCell Corporation's address is: 56 Evergreen Drive, Portland, ME, United States, 04103
What is ImmuCell Corporation's ISIN number?
ImmuCell Corporation's international securities identification number is: US4525253062
What is ImmuCell Corporation's CUSIP number?
ImmuCell Corporation's Committee on Uniform Securities Identification Procedures number is: 452525306

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site